<html xmlns:fo="http://www.w3.org/1999/XSL/Format">

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_atazanavir.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:24:49 GMT -->
<head>
<META http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<title>Johns Hopkins POC-IT: Point of Care Information Technology</title>
<meta content="text/html; charset=iso-8859-1" http-equiv="Content-Type">
<link href="../../images/styles.css" type="text/css" rel="stylesheet">
<script type="text/JavaScript" src="../../images/functions.js" language="JavaScript"></script>
</head>
<body>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td>Johns Hopkins POC-IT: Point of Care Information Technology</td><td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td></td><td>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td class="tdVAlignMiddle" align="center" >
                                                            &nbsp;</td>
</tr>
<tr></tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr>
<td  ><span class="mainNav">&nbsp;Print-Friendly Module</span></td>
</tr>
</table>
</td>
</tr>
</table>
<p></p>
<table cellspacing="0" cellpadding="0" border="0" >
<tr>
<td></td><td>
<table >
<tr>
<td><span class="primaryItemTitle"><font size="6">Atazanavir</font></span>
<br>
</td><td align="right" valign="top"><a href="javascript:window.print();"></a></td>
</tr>
<tr>
<td colspan="2">
<br>
        Author: <author maxOccurance="1" tag="author" use="required">Paul A. Pham, Pharm.D. and John G. Bartlett, M.D.</author>
<br>
<span class="display_date">04-24-2008</span>
<br>
<div style="background-color:#ccffcc;">
<a name=""></a>
<h2 class="grayLineHeaderBar"></h2>
<ul>
<li>Currently not available in Zambia. </li>
<li>A once-daily PI with good potency, GI tolerability, and favorable lipid effect. </li>
</ul>Zambia Information Author: Paul A. Pham, Pharm. D. <br>
<br>
</div>
<a name="INDICATIONS"></a>
<h2 class="grayLineHeaderBar">INDICATIONS</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">FDA</span></td>
</tr>
</table>
<hr>
<ul>
<li>Treatment of HIV infection in combination with other antiretroviral agents.</li>
</ul>
<a name="FORMS"></a>
<h2 class="grayLineHeaderBar">FORMS</h2>
<TABLE  class="blueOutline" cellspacing="0" cellpadding="2" border="0">
<TR class="blueBarBG">
<TD><B>brand name</B></TD><TD><B>preparation</B></TD><TD><B>manufacturer</B></TD><TD><B>route</B></TD><TD><B>form</B></TD><TD><B>dosage^</B></TD><TD><B>cost*</B></TD>
</TR>
        
<TR>
<TD valign="top">
            <I>Reyataz</I>
          </TD><TD valign="top">Atazanavir (ATV)</TD><TD valign="top">Bristol-Myers Squibb</TD><TD>oral</TD><TD>capsule</TD><TD>100 mg; 150 mg; 200 mg; 300 mg </TD><TD>$15.48 per 100 mg, 150 mg,or 200 mg&nbsp;cap. $30.97 per 300 mg </TD>
</TR>
      
</TABLE>
<p>*Costs (rounded to the nearest dollar) are based on usual adult dosing per day, 
                are representative of "Average Wholesale Price" (AWP), and are current within the prior three months.</p>
<p>^Dosage is indicated in mg unless otherwise noted.</p>
<a name="USUAL ADULT DOSING"></a>
<h2 class="grayLineHeaderBar">USUAL ADULT DOSING</h2>Pill burden: 2 caps/day PO (ATV 400 mg daily) or 3 caps/day (ATV 300 mg + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg daily).<br>
<br>
<ul>
<li>ATV 400 mg daily w/food (FDA-approved dose for treatment-naive pts;&nbsp;consider ATV/r 300/100 mg daily due to superior PK). ATV 400 mg daily (without RTV) not recommended with TDF, EFV, and NVP co-administration. </li>
<li>ATV300 mg + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg daily w/ food (FDA-approved dose for treatment experienced pts)</li>
<li>With <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>: ATV300 mg + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>100 mg daily + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> 600 mg qhs (may need to increase ATV dose in PI-experienced pts; consider TDM)</li>
<li>With <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>: ATV 300 mg + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg daily + <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF </A>300 mg daily.</li>
<li>With <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A>: ATV 400 mg + <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> 1200 mg daily (did not perform well in trials) or consider ATV 300 mg + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg + <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> 1500-2000 mg daily.</li>
<li>With <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A>: ATV 300 mg + <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A>&nbsp;400/100 mg bid.</li>
<li>No dosing recommendation with co-administration of other PIs (<A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>, <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A>, or <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>).</li>
<li>With <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A>: Avoid or consider TDM (studied regimen <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A> 1400 mg daily + ATV 400 mg daily). </li>
<li>With <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>: Consider ATV 300 mg + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg daily + standard dose <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>. PK study ongoing. </li>
<li>With TPV: ATV may be significantly decreased. Avoid co-administration. </li>
<li>With ETR: co-administration not recommended by manufacturer. </li>
</ul>
<a name="RENAL DOSING"></a>
<h2 class="grayLineHeaderBar">RENAL DOSING</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 50-80</span></td>
</tr>
</table>
<hr>No data. Usual dose likely. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 10-50</span></td>
</tr>
</table>
<hr>No data. Usual dose likely. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF &lt;10 ML/MIN</span></td>
</tr>
</table>
<hr>No data. Usual dose likely. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMODIALYSIS</span></td>
</tr>
</table>
<hr>No data. Usual dose likely. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN PERITONEAL DIALYSIS</span></td>
</tr>
</table>
<hr>No data. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMOFILTRATION</span></td>
</tr>
</table>
<hr>No data. <br>
<br>
<a name="ADVERSE DRUG REACTIONS"></a>
<h2 class="grayLineHeaderBar">ADVERSE DRUG REACTIONS</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">COMMON</span></td>
</tr>
</table>
<hr>
<ul>
<li>Common: reversible indirect hyperbilirubinemia, with grade 3-4 (&gt;2.6 x UNL) occurring in 35-47% of pts. Clinically benign: does not indicate liver disease and does not require discontinuation. Trough &gt;0.85 mcg/mL associated higher incidence of hyperbilirubinemia.</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">OCCASIONAL</span></td>
</tr>
</table>
<hr>
<ul>
<li>Jaundice with scleral icterus in up to 7-8% of pts. In comparison of ATV vs. ATV/r, grade 2-4 jaundice seen in &lt;1% on ATV, 3% on ATV/r.</li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/organ_system/nausea_vomiting1649.html?contentInstanceId=432759">Nausea, vomiting</A>, abdominal pain less common than with <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A>.</li>
<li>Rash, headache, mild transaminase elevation (unrelated to phase II conjugation UGT 1A1 inhibition).</li>
<li>Diabetes, <A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/hyperlipidemia4edb.html?contentInstanceId=434827">hyperlipidemia</A>: minimal or no effect on lipid profile or <A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/diabetes_mellitus_and_insulin_resistance382a.html?contentInstanceId=432783">insulin resistance</A>. Lipids slightly higher with RTV boosting.</li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/lipodystrophy94a9.html?contentInstanceId=432804">Lipodystrophy</A> listed, but it may be less likely to cause <A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/lipodystrophy94a9.html?contentInstanceId=432804">fat accumulation</A> than other PIs. </li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">RARE</span></td>
</tr>
</table>
<hr>
<ul>
<li>Dose dependent QTc and PR interval prolongation. Use with caution in pts with baseline altered cardiac conduction and with drugs that can alter cardiac conduction (i.e. diltiazem and <A class="headLines" target="_new" href="../antimicrobial_agents/clarithromycin2448.html?contentInstanceId=434158">clarithromycin</A>; see drug-drug interaction section for dosing recommendation). </li>
<li>Studies with ATV/r 300/100 mg qd showed slight but not significant increases in PR interval averaging 3 msec and no change at 1 month. </li>
</ul>
<a name="DRUG INTERACTIONS"></a>
<h2 class="grayLineHeaderBar">DRUG INTERACTIONS</h2>Substrate and inhibitor of CYP3A4.Weak inhibitor of CYP1A2 and CYP2C9 <I>in vitro </I>but clinical significance unknown. Inhibitor of phase II conjugation (UGT1A1). CYP3A4 inhibitors may increase ATV levels. CYP3A4 inducers may decrease ATV levels. ATV may increase levels of CYP3A4 substrates. NRTI levels generally not affected by ATV.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">Drug-to-Drug Interactions</span></td>
</tr>
</table>
<hr>
<a name="Drug-to-Drug Interaction"></a>
<h2 class="grayLineHeaderBar">Drug-to-Drug Interaction</h2>
<TABLE class="blueOutline" CELLPADDING="2" CELLSPACING="0"  BORDER="0">
<tr class="blueBarBG">
<td>Drug</td><td>Effect of Interaction</td><td>Recommendations/Comments</td>
</tr>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/clarithromycin2448.html?contentInstanceId=434158">Clarithromycin</A>
          </B></TD><TD valign="top">ATV AUC increased by 28%. <A class="headLines" target="_new" href="../antimicrobial_agents/clarithromycin2448.html?contentInstanceId=434158">Clarithromycin</A> AUC increased by 94%. 14-hydroxyclarithromycin metabolite AUC decreased by 70%.</TD><TD valign="top">QTc prolongation observed with co-administration. 50% of <A class="headLines" target="_new" href="../antimicrobial_agents/clarithromycin2448.html?contentInstanceId=434158">clarithromycin</A> dose recommended. Consider <A class="headLines" target="_new" href="../antimicrobial_agents/azithromycin9ba3.html?contentInstanceId=441410">azithromycin</A>.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/rifampicin532e.html?contentInstanceId=434653">Rifampin</A>
          </B></TD><TD valign="top">ATV may be significantly decreased.</TD><TD valign="top">Co-administration with <A class="headLines" target="_new" href="../antimicrobial_agents/rifampicin532e.html?contentInstanceId=434653">rifampin </A>not recommended. Rifabutin may be safer alternative. Dose: ATV 400 mg daily +?rifabutin 150 mg 3x/week.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">Fosamprenavir</A>
          </B></TD><TD valign="top">ATV AUC decreased by 33%. APV AUC increased by 78%. (Dose studied: FPV 1400 mg daily + ATV 400 mg daily) </TD><TD valign="top">Clinical significance unknown. Avoid or consider TDM in PI-experienced patients. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="darunavir4a48.html?contentInstanceId=443123">Darunavir</A>
          </B></TD><TD valign="top">No significant interaction </TD><TD valign="top">Dose: <A class="headLines" target="_new" href="darunavir4a48.html?contentInstanceId=443123">Darunavir</A> 600/100 mg bid plus ATV 300 mg qd </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/fluconazoled462.html?contentInstanceId=434183">Fluconazole</A>
          </B></TD><TD valign="top">No significant interaction </TD><TD valign="top">Use standard dose </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="tipranavir9ea2.html?contentInstanceId=443122">Tipranavir</A>
          </B></TD><TD valign="top">ATV may be significantly decreased </TD><TD valign="top">Avoid co-administration </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">Abacavir</A>
          </B></TD><TD valign="top">ABC plasma concentration decreased by 17%. </TD><TD valign="top">Unknown mechanisms and clinical implications. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="etravirine4427.html?contentInstanceId=443125">Etravirine</A>
          </B></TD><TD valign="top">With unboosted ATV: ETV AUC increased by 50%, but ATV Cmin decreased by 47%. With ATV/r: ETV AUC increased by 30% and ATV AUC and Cmin decreased by 14% and 38%, respectively. </TD><TD valign="top">Avoid with unboosted ATV with ETR co-administration. Unclear clinical significance with ATV/r, but the manufacturer recommends avoiding co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">Lopinavir</A>/<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">ritonavir</A> (<A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A>) </B></TD><TD valign="top">ATV geometric mean Cmin increased by 45% with <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> 400/100 mg BID co-administration (compared to ATV/r 300/100 mg daily). LPV PK comparable to historical data. </TD><TD valign="top">Dose: ATV 300 mg daily + <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> 400/100 mg BID. </TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">Didanosine</A> (<A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI</A>) (buffered)</B></TD><TD valign="top">No effect on <A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI</A> serum level. ATV AUC decreased by 87%, Cmin decreased by 84% (single dose study ATV 400 mg x1 with <A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI</A> buffered 200 mg x1).</TD><TD valign="top">Administer ATV 400 mg one hr after <A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI</A> (buffered) administration. Consider <A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI</A> EC.</TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">Efavirenz</A> (<A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>)</B></TD><TD valign="top">ATV AUC decreased by 74%, Cmax decreased by 59%, Cmin decreased by 93%.</TD><TD valign="top">Co-administration of ATV as a sole PI with <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> not recommended. Boosting ATV 300 mg +<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg daily recommended with co-administration of standard dose of <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>.</TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">Ritonavir</A> (<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>)</B></TD><TD valign="top">ATV AUC increased by 238%, Cmin increased by 1089% (Dose:ATV 300 mg + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg qd).</TD><TD valign="top">Boosting ATV 300 mg with 100 mg <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV </A>results in better PK profile (doubles total ATV exposure and increases ATV trough by 10-fold), which may be preferred in?PI-experienced pts.</TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">Saquinavir</A> (<A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A>)</B></TD><TD valign="top"><A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> AUC increased by 449% (<A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> dosed at 1200 mg qd with ATV 400 mg qd) ATV not measured.</TD><TD valign="top">Beneficial PK interactions which allows daily administration of <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A>, but combination was inferior to <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A>. ATV 400 mg + <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> 1200 mg qd (did not perform well in?trials). Consider ATV 300 mg + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg + <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> 1500-2000 mg qd.</TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">Nevirapine</A>&nbsp;(NVP) </B></TD><TD valign="top">Unboosted ATV Cmin was significantly lower with NVP co-administration. </TD><TD valign="top">An observational study suggests that ATV should be boosted (ATV?RTV 300/100mg daily) with NVP co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">Tenofovir</A> (TDF)</B></TD><TD valign="top">ATV AUC decreased by 28% (compared to boosted ATV 300 mg/<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>?100 mg), but still significantly (200%) higher than unboosted ATV. <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A> not measured.</TD><TD valign="top">Interaction unlikely to be significant when ATV is boosted due to high ATV concentrations achieved with additional <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> (100 mg). Avoid use of <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A> with unboosted ATV. If co-administered with TDF + famotidine 20 mg bid, increase ATV/r to 400/100 mg) qd.</TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">Zidovudine (AZT</A>)<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">Lamivudine (3TC</A>)</B></TD><TD valign="top"><A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A> and <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> unaffected. ATV not studied.</TD><TD valign="top">Standard dose <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/ <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> with ATV.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Alprazolam
          </B></TD><TD valign="top">May increase serum level of alprazolam.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider alternative benzodiazepines (i.e lorazepam, oxazepam, or temazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Amiodarone</B></TD><TD valign="top">May significantly increase amiodarone serum level.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to case report of increased amiodarone levels with <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> co-administration. ATV not recommended to be co-administered with amiodarone. If co-administration can not be avoided, monitor for amiodarone ADR (PFTs, TSH). Consider monitoring serum level of amiodarone, but its long half-life may make titration difficult.</TD>
</TR>
<TR>
<TD valign="top"><B>Amlodipine</B></TD><TD valign="top">May increase serum level of amlodipine.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with ATV and diltiazem which resulted in doubling of diltiazem serum level (this led to PR interval prolongation). All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the potential for prolonging the PR interval with Ca channel blocker co-administration. Ca channel blockers should be started with a low dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Antacids</B></TD><TD valign="top">May significantly decrease in ATV serum levels.</TD><TD valign="top">Avoid co-administration. Separate administration time, ATV 400 mg 2 hrs before AC or 1 hr after buffered <A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI</A> or antacid administration.</TD>
</TR>
<TR>
<TD valign="top"><B>Artemether (artemisinin)</B></TD><TD valign="top">May increase serum level of artemether.</TD><TD valign="top">Applies to All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Close monitoring for artemether toxicity (bone marrow suppression, bradycardia and seizure).</TD>
</TR>
<TR>
<TD valign="top"><B>Astemizole</B></TD><TD valign="top">May significantly increase astemizole serum level.</TD><TD valign="top">Contraindicated due to potential for cardiac arrhythmias. Recommended alternative antihistamine: loratadine, fexofenadine, desloratidine, or cetirizine.</TD>
</TR>
<TR>
<TD valign="top"><B>Atenolol</B></TD><TD valign="top">Atenolol AUC increased by 25%; Cmin: no significant change. ATV not affected.</TD><TD valign="top">No effect on PR or QTc interval with co-administration. Start with low dose atenolol with slow dose titration.</TD>
</TR>
<TR>
<TD valign="top"><B>Azathioprine</B></TD><TD valign="top">Interaction unlikely.</TD><TD valign="top">Applies to all PIs and NNRTI: Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>Bepridil</B></TD><TD valign="top">May significantly increase bepridil serum level.</TD><TD valign="top">The manufacturer of ATV does not recommend bepridil co-administration; this contraindication should extend to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> since a significant increase in bepridil serum level can result in pro-arrhythmic events such as VT, PVC, and VFib.</TD>
</TR>
<TR>
<TD valign="top"><B>Carbamazepine</B></TD><TD valign="top">May decrease serum levels of ATV.</TD><TD valign="top">Consider alternative anticonvulsants (i.e valproic acid, lamotrigine, levetiracetam, or topiramate). With co-administration, monitor anticonvulsants level and consider TDM of ATV.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Chlordiazepoxide
          </B></TD><TD valign="top">May increase serum level of chlordiazepoxide.</TD><TD valign="top">Applies to all PIs and DLV: Consider alternative benzodiazepines (i.e lorazepam, temazepam, or oxazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Cisapride</B></TD><TD valign="top">May significantly increase cisapride serum level.</TD><TD valign="top">Contraindicated due to potential for cardiac arrhythmias. Recommended alternative: metoclopramide.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Clorazepate
          </B></TD><TD valign="top">May increase serum level of clorazepate.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider alternative benzodiazepines (i.e lorazepam, temazepam, or oxazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Cyclophosphamide</B></TD><TD valign="top">May increase serum level of cyclophosphamide.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> resulting in a 50% increase in cyclophosphamide serum level. Since all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have potential of increasing cyclophosphamide levels, close monitoring of cyclophosphamide-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Cyclosporine</B></TD><TD valign="top">May significantly increase serum level of cyclosporine.</TD><TD valign="top">Applies to all PIs: Monitor serum level of cyclosporine closely with co-administration. Cyclosporine dose may need to be decreased.</TD>
</TR>
<TR>
<TD valign="top"><B>Digoxin </B></TD><TD valign="top">Digoxin AUC may be increased with ATV/r co-administration </TD><TD valign="top">Monitoring of digoxin concentration closely. Digoxin dose may need to be reduced. </TD>
</TR>
<TR>
<TD valign="top"><B>Diltiazem</B></TD><TD valign="top">Diltiazem AUC increased by 125%. Desacetyl diltiazem (active metabolite) AUC increased by 165%. ATV not affected.</TD><TD valign="top">PR interval prolongation observed. Start with 50% of diltiazem dose and titrate slowly with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Disopyramide</B></TD><TD valign="top">May increase disopyramide serum levels.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Monitor disopyramide serum level (target: 2 to 7.5 mcg/mL).</TD>
</TR>
<TR>
<TD valign="top"><B>Docetaxel</B></TD><TD valign="top">May increase serum level of docetaxel.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of chemotherapy induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Dofetilide</B></TD><TD valign="top">May significantly increase serum level of dofetilide.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Use with caution. Monitor QTc closely and adjust dofetilide dosing based on QTc prolongation and renal function. Consider an alternative class III antiarrhythmic such as bretylium or ibutilide.</TD>
</TR>
<TR>
<TD valign="top"><B>Echinacea </B></TD><TD valign="top">May decrease ATV serum level. Echinacea (400 mg 4xd) decreased CYP3A4 substrate (midazolam) by 23%.</TD><TD valign="top">Applies to all PIs and NNRTIs. Clinical significance unknown but should avoided until the safety of this combination is further evaluated.</TD>
</TR>
<TR>
<TD valign="top"><B>Ergot Alkaloid</B></TD><TD valign="top">May significantly increase serum level of ergotamine resulting in acute ergot toxicity.</TD><TD valign="top">Contraindicated. Consider alternative agent for migraine such as sumatriptan (but not eletriptan since it is a CYP3A4 substrate and significant drug-drug interaction occurred with a CYP3A4 inhibitor).</TD>
</TR>
<TR>
<TD valign="top"><B>
            Estazolam
          </B></TD><TD valign="top">May increase serum level of estazolam.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider alternative benzodiazepines (i.e lorazepam, temazepam, or oxazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Ethinyl estradiol and norethindrone</B></TD><TD valign="top">Norethindrone Cmax: increased 67%; AUC: increased 110%; Cmin: increased 262%; Ethinyl estradiol AUC: increased 48%; Cmax: no significant change; Cmin: increased 91%.</TD><TD valign="top">Clinical significance unknown. Monitor for OC adverse drug reaction. Consider alternative contraceptive methods.</TD>
</TR>
<TR>
<TD valign="top"><B>Ethosuximide</B></TD><TD valign="top">May increase serum levels of ethosuximide.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider switching to valproic acid for the treatment of absence seizure.</TD>
</TR>
<TR>
<TD valign="top"><B>Etoposide</B></TD><TD valign="top">May increase serum level of etoposide.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of chemotherapy induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Felodipine</B></TD><TD valign="top">May increase serum level of felodipine.</TD><TD valign="top">Applies to all PIs and<A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124"> DLV</A>: Data limited to an interaction study conducted with ATV and diltiazem which resulted in doubling of diltiazem serum level (this led PR interval prolongation). All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have potential of prolonging PR interval with Ca channel blocker co-administration. Ca channel blockers should be started with low dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Fentanyl
          </B></TD><TD valign="top">May significantly increase fentanyl serum level.</TD><TD valign="top">Use with caution. Consider morphine.</TD>
</TR>
<TR>
<TD valign="top"><B>Flecainide</B></TD><TD valign="top">May increase antiarrhythmic serum level.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Avoid co-administration; if necessary, monitor flecainide trough level with co-administration. Target: 200-1000 ng/mL. Toxicity frequent with trough serum levels above 1000 ng/mL.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Flurazepam
          </B></TD><TD valign="top">May increase serum level of flurazepam.</TD><TD valign="top">Applies to All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider alternative benzodiazepines (i.e lorazepam, temazepam, or oxazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Food (light meal)</B></TD><TD valign="top">ATV AUC increased by 70%.</TD><TD valign="top">ATV should be administered with food.</TD>
</TR>
<TR>
<TD valign="top"><B>Garlic supplement </B></TD><TD valign="top">No data.</TD><TD valign="top">Studies only done with <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> resulting in <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> serum level reduction. No data with other PIs or NNRTIs. Avoid co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>Granisetron</B></TD><TD valign="top">May increase serum level of granisetron.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Due to the large therapeutic index of granisetron, potential interaction unlikely to be clinically significant.</TD>
</TR>
<TR>
<TD valign="top"><B>H2 blocker</B></TD><TD valign="top">ATV/r + famotidine: Cmin decreased by 28% (but comparable to ATV/r Cmin when co-administered with TDF) </TD><TD valign="top">Avoid co-administration if possible. If ATV/r (300/100 mg) is co-administered with famotidine, the max recommended dose for ARV-naive pts is famotidine 40 mg bid. Max dose for ARV-experienced pts is famotidine 20 mg bid with ATV/r co-administration. Administer ATV 2 hrs before or 10 hrs after H2 blocker is preferred. If co-administered with TDF + famotidine 20 mg bid, increase ATV/r to 400/100 mg) qd.</TD>
</TR>
<TR>
<TD valign="top"><B>Heroin (Diamorphine)</B></TD><TD valign="top">Drug interactions unlikely.</TD><TD valign="top">Applies to PIs and NNRTIs: Interaction unlikely but illicit drug use should be avoided for obvious reasons.</TD>
</TR>
<TR>
<TD valign="top"><B>Ifosfamide</B></TD><TD valign="top">May increase serum level of ifosfamide.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of chemotherapy-induced toxicity recommended. </TD>
</TR>
<TR>
<TD valign="top"><B>Irinotecan </B></TD><TD valign="top">May increase irinotecan serum level.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: <BR>Co-administration of ATV is contraindicated by manufacturer. </TD>
</TR>
<TR>
<TD valign="top"><B>
            Itraconazole
          </B></TD><TD valign="top">CYP3A4 inhibitor and substrate - potential for bidirectional inhibition with increase levels of PIs and itraconazole. </TD><TD valign="top">Except for <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>, there are no recommendations for dose adjustment for other PIs or NNRTIs. Reduce <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV </A>dose to 600 mg q8h and do not exceed 400 mg/d of itraconazole. No data with <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> / <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> co-administration. Consider <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> 800 mg BID +<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950"> RTV</A> 100 mg BID with aggressive hydration due to the potential increased risk of nephrolithiasis. </TD>
</TR>
<TR>
<TD valign="top"><B>
            Ketoconazole
          </B></TD><TD valign="top">ATV unaffected. Ketoconazole not studied.</TD><TD valign="top">Standard dose ATV with ketoconazole co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>Lidocaine</B></TD><TD valign="top">May increase antiarrhythmic serum levels.</TD><TD valign="top">Applies to all PIs and DLV: No data. Use with caution, monitor lidocaine serum level (target: 1.5 to 6 mcg/mL) with co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>
            Lovastatin
          </B></TD><TD valign="top">Serum levels of lovastatin may be significantly increased.</TD><TD valign="top">Contraindicated. Recommended alternatives include pravastatin, rosuvastatin, and fluvastatin (and possibly atorvastatin- start with 10 mg/day). Monitor for adverse effect due to limited clinical data.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Mefloquine
          </B></TD><TD valign="top">May increase serum levels of mefloquine.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: If available consider mefloquine serum level monitoring. Monitor for mefloquine toxicity (i.e dizziness, LFTs, and periodic ophthalmic examination).</TD>
</TR>
<TR>
<TD valign="top"><B>
            Methadone
          </B></TD><TD valign="top">No data.</TD><TD valign="top">Interaction unlikely but should monitor for sedation with co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>Mexiletine</B></TD><TD valign="top">May increase antiarrhythmic serum levels.</TD><TD valign="top">Applies to all PIs and DLV: No data. Use with caution. Monitor EKG and serum level. Serum levels exceeding 1.5 to 2 mcg/mL have been associated with an increased risk of toxicity.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Midazolam
          </B></TD><TD valign="top">May significantly increase midazolam level.</TD><TD valign="top">Concurrent administration of midazolam is contraindicated. Consider alternative benzodiazepines (temazepam, oxazepam, or lorazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Milk thistle </B></TD><TD valign="top">No data.</TD><TD valign="top">Data limited to an interaction study with milk thistle and <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>. <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> AUC: unchanged; <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> Cmin: decreased by 47% Clinical significance unknown. Unknown effect of the metabolism of other PIs or NNRTIs. Avoid co-administration with PIs and NNRTIs until it can be further evaluated. </TD>
</TR>
<TR>
<TD valign="top"><B>Mirtazapine</B></TD><TD valign="top">May increase serum level of mirtazapine.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Use with caution. Consider an alternative antidepressant (i.e SSRI: escitalopram, citalopram, sertraline, or fluoxetine).</TD>
</TR>
<TR>
<TD valign="top"><B>Mycophenolate</B></TD><TD valign="top">Interaction unlikely. No significant interaction observed with <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>.</TD><TD valign="top">Applies to all PIs and NNRTIs: No significant interaction observed with NVP. Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>Nefazodone</B></TD><TD valign="top">May increase serum level of nefazodone.</TD><TD valign="top">Applies to all PIs and<A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124"> DLV</A>: Use with caution. Consider an alternative antidepressant (i.e SSRI: escitalopram, citalopram, sertraline, or fluoxetine).</TD>
</TR>
<TR>
<TD valign="top"><B>Nifedipine</B></TD><TD valign="top">May increase serum level of nifedipine.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with ATV and diltiazem which resulted in doubling of diltiazem serum level (this led to PR interval prolongation). All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have potential of prolonging the PR interval with Ca channel blocker co-administration. Ca channel blockers should be started at low dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Nisoldipine</B></TD><TD valign="top">May increase serum level of nisoldipine.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with ATV and diltiazem which resulted in doubling of diltiazem serum level (this led to PR interval prolongation). All PIs and DLV have potential of prolonging the PR interval with Ca channel blockers co-administration. Ca channel blockers should be started at low dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Paclitaxel
          </B></TD><TD valign="top">May increase paclitaxel serum level.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to case reports of severe toxicity-associated with <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> and <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> co-administration with paclitaxel. Since all PIs have the potential of significantly increasing paclitaxel serum level, close monitoring of paclitaxel-induced toxicity is recommended. </TD>
</TR>
<TR>
<TD valign="top"><B>PCP</B></TD><TD valign="top">May significantly increase serum level of PCP.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Avoid PCP use with PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> (and all Illicit drug use for obvious reasons).</TD>
</TR>
<TR>
<TD valign="top"><B>Phenobarbital</B></TD><TD valign="top">May decrease serum levels of ATV.</TD><TD valign="top">Consider alternative anticonvulsants (i.e valproic acid, lamotrigine, levetiracetam, or topiramate). With co-administration, monitor anticonvulsants level and consider TDM of ATV.</TD>
</TR>
<TR>
<TD valign="top"><B>Phenytoin</B></TD><TD valign="top">May decrease serum levels of ATV.</TD><TD valign="top">Consider alternative anticonvulsants (i.e valproic acid, lamotrigine, levetiracetam, or topiramate). With co-administration, monitor anticonvulsants level and consider TDM of ATV.</TD>
</TR>
<TR>
<TD valign="top"><B>Pimozide</B></TD><TD valign="top">May significantly increase pimozide serum level resulting in QTc prolongation.</TD><TD valign="top">Contraindicated. Consider alternative: olanzapine.</TD>
</TR>
<TR>
<TD valign="top"><B>PPI (omeprazole)</B></TD><TD valign="top">ATV Cmin decreased by 78%. Cmin decreased by 46% if separated by 12 hours. </TD><TD valign="top">Co-administration of PPI and ATV is contraindicated in ARV-experienced pts. In ARV-naive pts, ATV/r (300/100mg) + Omeprazole 20 mg (separated by 12 hours) may be considered, but not recommended by author. </TD>
</TR>
<TR>
<TD valign="top"><B>Propafenone</B></TD><TD valign="top">May increase antiarrhythmic serum levels.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Co-administration should be avoided. Serum levels are not routinely recommended due to the poor correlation with efficacy and toxicity.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Quinidine
          </B></TD><TD valign="top">May increase antiarrhythmic serum levels.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Contraindicated with <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>. With all PIs and NNRTIs co-administration, monitor EKG (QTc) and serum level: Target: 2 to 5 mcg/mL.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Rifabutin&nbsp;(RFB)
          </B></TD><TD valign="top">Rifabutin (RFB) AUC increased by 110%, Cmin increased by 243% (with RFB 150 mg qd) ATV AUC increased by 191%.</TD><TD valign="top">Recommended dosing with co-administration: ATV 400 mg qd with RFB 150 mg 3x/wk. Or ATV/<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>300/100 mg daily with RFB 150 mg 3x/wk.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Rifapentine
          </B></TD><TD valign="top">ATV serum levels may be significantly decreased.</TD><TD valign="top">Avoid co-administration. Consider using rifabutin.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Rosuvastatin
          </B></TD><TD valign="top">Other CYP3A4 inhibitor (i.e <A class="headLines" target="_new" href="../antimicrobial_agents/erythromycin329b.html?contentInstanceId=434157">erythromycin</A>) did not affect rosuvastatin serum level.</TD><TD valign="top">Applies to PIs and NNRTIs: Interaction unlikely, but close monitoring recommended due to limited clinical data.</TD>
</TR>
<TR>
<TD valign="top"><B>Sildenafil</B></TD><TD valign="top">May increase sildenafil serum level.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Use with close monitoring. Do not exceed 25 mg in a 48 hr period.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Simvastatin
          </B></TD><TD valign="top">May significantly increase simvastatin levels.</TD><TD valign="top">Contraindicated. Alternative that may be used include atorvastatin, pravastatin, rosuvastatin, fluvastatin. Monitor for adverse effect due to limited clinical data.</TD>
</TR>
<TR>
<TD valign="top"><B>Sirolimus</B></TD><TD valign="top">May significantly increase serum level of sirolimus.</TD><TD valign="top">Applies to all PIs: Dose sirolimus based on serum level. A significantly reduction of sirolimus dose with co-administration of all PIs is highly likely.</TD>
</TR>
<TR>
<TD valign="top"><B>St. John's wort</B></TD><TD valign="top">May significantly decrease ATV serum level.</TD><TD valign="top">Contraindicated. Studies only done with <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> but St John's wort may affect the metabolism of other PIs and NNRTIs. Use an alternative (more effective) antidepressant.</TD>
</TR>
<TR>
<TD valign="top"><B>Tacrolimus</B></TD><TD valign="top">May significantly increase serum level of tacrolimus.</TD><TD valign="top">Applies to all PIs: Dose tacrolimus based on serum level. A significantly reduction of tacrolimus dose with all PIs co-administration is recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Tadalafil</B></TD><TD valign="top">May increase serum level of tadalafil.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Start with 5 mg. Do not exceed 10 mg in 72 hrs. Consider sildenafil due to more clinical data and shorter half-life allowing for easier titration.</TD>
</TR>
<TR>
<TD valign="top"><B>Tamoxifen</B></TD><TD valign="top">May increase serum level of tamoxifen.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of tamoxifen induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Teniposide</B></TD><TD valign="top">May increase serum level of teniposide.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of teniposide-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Terfenadine</B></TD><TD valign="top">May significantly increase terfenadine serum level.</TD><TD valign="top">Contraindicated due to the potential for cardiac arrhythmias. Recommended alternative antihistamine: loratadine, fexofenadine, desloratidine, or cetirizine.</TD>
</TR>
<TR>
<TD valign="top"><B>THC</B></TD><TD valign="top">Based on data with <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV </A>and <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> interactions are unlikely.</TD><TD valign="top">Applies to PIs and NNRTIs: Interactions are unlikely.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Trazadone
          </B></TD><TD valign="top">May increase serum level of trazadone.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Use with caution. Consider alternative antidepressant (i.e SSRI: escitalopram, citalopram, sertraline, or fluoxetine).</TD>
</TR>
<TR>
<TD valign="top"><B>
            Triazolam
          </B></TD><TD valign="top">May significantly increase triazolam serum level.</TD><TD valign="top">Contraindicated. Consider alternative benzodiazepines (temazepam, oxazepam, or lorazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Vardenafil</B></TD><TD valign="top">May significantly increase serum level of vardenafil.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Do not exceed vardenafil 2.5 mg in 72 hrs (with <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>) or 2.5 mg in 24 hrs (with other PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>). Consider sildenafil due to more clinical data and less pronounced interaction. </TD>
</TR>
<TR>
<TD valign="top"><B>Verapamil</B></TD><TD valign="top">May increase serum level of verapamil.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with ATV and diltiazem which resulted in doubling of diltiazem serum level (this led to PR interval prolongation). All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the potential of prolonging the PR interval with Ca channel blocker co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Vinblastine</B></TD><TD valign="top">May increase serum level of vinblastine.</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of vinblastine-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Vincristine</B></TD><TD valign="top">May increase serum level of vincristine.</TD><TD valign="top">Applies to all PIs and DLV: No data. Close monitoring of vincristine-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Vitamin C </B></TD><TD valign="top">No data.</TD><TD valign="top">Data limited to interaction study with <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV </A>and vitamin C (1 g/d) resulting in <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV </A>AUC decreased by 14% and Cmin by 32%. Avoid co-administration until more data available.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Voriconazole
          </B></TD><TD valign="top">May decrease voriconazole AUC. Voriconazole may increase co-administered ATV.</TD><TD valign="top">Significant interaction with <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> and <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> (400 mg bid). ?Low dose <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> boosting (200 mg/d) decreased voriconazole AUC by 39%; co-administration should be avoided or should be used with caution. In severe cases of invasive<A class="headLines" target="_new" href="../../pathogens/fungi/aspergillus_spp.35f5.html?contentInstanceId=432288"> aspergillosis</A>?the addition or substitution of voriconazole with ambisome or caspofungin should be considered</TD>
</TR>
</TABLE>
<a name="SPECTRUM"></a>
<h2 class="grayLineHeaderBar">SPECTRUM</h2>
<a name="N10F38"></a>
<TABLE CELLPADDING="0" CELLSPACING="0"  BORDER="0"></TABLE>
<ul>
<li>HIV </li>
</ul>
<a name="RESISTANCE"></a>
<h2 class="grayLineHeaderBar">RESISTANCE</h2>
<ul>
<li>I50L: unique primary ATV mutation, selected by unboosted ATV. Results in intermediate resistance to ATV but susceptibility (or hypersusceptibility) to other PIs. Typically followed by A71V (in 40% of pts). Limited data suggest that PI resistance less common with failure of ATV/r as initial PI. </li>
<li>L10Y/F, I50L, L63P, A71V, N88S, V32I, M46I, I84V, and L89M: 4-5 of the following mutations resulted in &gt;90-fold resistance to ATV <I>in vitro. </I>
</li>
<li>PI mutations (L33F, 82A/F/T/S, 84V/A/C, 90M, 46I/L) and (L10I/F/V, K20R/M/I, L24I, V32I, M36I/L/V, I50L, I54V, L63P, A71V, G73C/S/T/A) <U>&gt;</U>4 mutations: decreased potency of ATV (post-hoc analysis of 045 study).</li>
<li>ATV mutation score: 10F/I/V, 16E, 33F/I/V, 46I/L, 60E, I84V, 85V, and 90M. Response: 0-1 mutation=100%; 2 mutation=80%; 3 mutations=42%; 4 mutations=0%. </li>
</ul>
<a name="PHARMACOLOGY"></a>
<h2 class="grayLineHeaderBar">PHARMACOLOGY</h2>
<a name="N10F63"></a>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">MECHANISM</span></td>
</tr>
</table>
<hr>Inhibition of HIV protease, which results in nonfunctional, immature and non-infectious virions. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PHARMACOKINETIC PARAMETERS</span></td>
</tr>
</table>
<hr>
<ul>
<li>Absorption: 
                Well absorbed with food.</li>
<li>Metabolism and Excretion: 
                CYP 3A4 substrate and inhibitor. Metabolized to 2 inactive metabolites and excreted primarily via biliary excretion. 13% of ATV and/or its metabolites are excreted in the urine.</li>
<li>Protein Binding: 
                86% </li>
<li>Cmax, Cmin, and AUC: 
                Mean Cmax=3.152 mcg/mL; Cmin=0.273 mcg/mL; AUC = 22.3 mcg hr/mL (ATV 400 mg qd at steady-state). Cmin 0.15-0.85 mcg/mL associated with good response. </li>
<li>T1/2: 
                6.5 hrs</li>
<li>Distribution: 
                Highly variable and poor CNS penetration. Poor seminal fluid penetration. </li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR DECREASED HEPATIC FUNCTION</span></td>
</tr>
</table>
<hr>ATV AUC increased by 45% with mild to moderate hepatic insufficiency. Consider decreasing dose to ATV to 300mg daily, but no clinical data.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PREGNANCY RISK</span></td>
</tr>
</table>
<hr>Category B. No human data. In animal studies, ATV did not result in embryonic or fetal toxicity when given maternally toxic doses.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">BREAST FEEDING COMPATIBILITY</span></td>
</tr>
</table>
<hr>No data.<a name="COMMENTS"></a>
<h2 class="grayLineHeaderBar">COMMENTS</h2>
<ul>
<li>Pros: Good potency, especially when boosted with <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>; lowest pill burden for a PI regimen; once daily regimen; no effects on lipids; good GI tolerability; less likely to cause <A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/diabetes_mellitus_and_insulin_resistance382a.html?contentInstanceId=432783">insulin resistance</A> and <A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/lipodystrophy94a9.html?contentInstanceId=432804">fat accumulation</A> (limited data); resistance profile favorable with failure of unboosted ATV in PI-naive pts, and PI resistance may be uncommon with failure of ATV/r. ATV/r comparable to <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> in PI-experienced pts at 96 wks.</li>
<li>Cons: Less long -term efficacy data than with <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A>; jaundice or scleral icterus may be problematic for some pts; drug interactions with PPIs, H2 blocker, and antacids (contraindicated with PPIs); food requirement. RTV-boosting may improve potency, but with slight increase in lipids and jaundice vs. unboosted ATV.</li>
</ul>
<a name="N10FB9"></a><a name="References"></a>
<h2 class="grayLineHeaderBar">References</h2>
<ol>
<li>Malan N, Krantz E, David N, et al. ;
		Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089 ;        
		13th CROI, Denver, Colorado. 2006; Abstract 107LB. ;
		2006; Vol. 
		<br>
<b>Comments:</b>AI424-089, which compared the efficacy and safety of ATV/r 300/100 mg with ATV 400 mg, both in combination with 3TC and <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">d4T</A>XR, all daily, in ART-naive subjects. At 96-wks, response rates were comparable between boosted and unboosted ATV (IT, &lt;50were 75% and 70%, respectively). However, study was not powered to determine non-inferiority of ATV vs. ATV/r and were numerically more virologic failures in ATV arm, with more apparent PI and NRTI resistance. Jaundice more common in ATV/r arm, and lipids somewhat higher, though few pts required lipid-lowering therapy. <br>
<br>
</li>
<li>Johnson M, Grinsztejn B, Rodriguez C, et al.;
		Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.;        
		AIDS;
		2005; Vol. 
		19; pp. 
		685-94;
		<br>ISSN:
	        	0269-9370;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=15821394&amp;dopt=abstract" target="_new">15821394</a>
<br>
<b>Comments:</b>358 pts who had failed at least 2 HAART regimens containing at least 1 PI, NNRTI, and NRTI randomized to ATV/<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 300/100 mg qd, ATV/<A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> 400/1200 mg qd, or <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> 400 mg100 mg bid each combined with <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A> plus 1 NRTI. At 48 wks, 58% vs 56% achieved VL &lt;400 in <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> and ATV/<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> arm, respectively. Trend favoring <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A>, with 46% vs 38% achieving VL endpoint of &lt;50, but not statistically significant. ATV/<A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> arm did not perform as well as other 2 groups. Note that not all pts in this trial were heavily PI-experienced. Only 33% of the ATV/<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> arm and 37% of the <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> arm had &gt;4 PI mutations (10, 20, 24, 32, 33, 36, 46, 50, 54, 63, 71, 73, 82, 84, 90). In a post-hoc analysis of these pts with &gt;4 PI mutations at baseline, <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> regimen demonstrated greater decline in VL compared to the ATV/<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> arm (1.47 log and 1.38, respectively). The limitation of this genotypic analysis is that the percent of critical PI mutation (i.e 32, 33, 54, 82, 84, and 90) in each group is not known. In addition, only 1/3 of pts were on a PI-containing regimen at the time of the genotype analysis. The post-hoc analysis of the more heavily PI-experienced pts was under powered to show difference between 2 groups. For the mean time it is safe to say that boosted-ATV is non-inferior to <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> in moderately PI-experienced pts, and these data can probably be extrapolated to PI-naive pts as well. <br>
<br>
</li>
<li>Cohen C, Nieto-Cisneros L, Zala C, et al.;
		Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.;        
		Curr Med Res Opin;
		2005; Vol. 
		21; pp. 
		1683-92;
		<br>ISSN:
	        	0300-7995;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=16238909&amp;dopt=abstract" target="_new">16238909</a>
<br>
<b>Comments:</b>Phase III trial that compared ATV (400 mg qd) with <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> (400/100 mg bid), each in combination with 2 NRTIs, in 300 treatment-experienced pts with virologic failure following a single PI-based regimen. At 24 wks <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> showed a better virologic response: 75% vs 54% with VL&lt;400 and 50% vs 34% with VL&lt;50. Unboosted ATV is inferior to <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> and should not be used in PI-experienced pts. <br>
<br>
</li>
<li>Wood R, Phanuphak P, Cahn P, et al.;
		Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir.;        
		J Acquir Immune Defic Syndr;
		2004; Vol. 
		36; pp. 
		684-92;
		<br>ISSN:
	        	1525-4135;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=15167287&amp;dopt=abstract" target="_new">15167287</a>
<br>
<b>Comments:</b>Switch study in which NFV recipients in BMS 008 (ATV vs. <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A>) were offered ATV at 72 wks. The 63 participants who selected switch option showed sustained antiviral effect and a significantly better lipid profile with mean decreases in total and LDL cholesterol at 24 wks of 31 mg/dL and 33 mg/dL, respectively. Of the total 346 pts who received ATV, only 2% discontinued due to adverse events (with avg. follow-up of 108 wks). <br>
<br>
</li>
<li>Squires K, Lazzarin A, Gatell JM, et al.;
		Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.;        
		J Acquir Immune Defic Syndr;
		2004; Vol. 
		36; pp. 
		1011-9;
		<br>ISSN:
	        	1525-4135;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=15247553&amp;dopt=abstract" target="_new">15247553</a>
<br>
<b>Comments:</b>BMS 034, which compared EFV and ATV each with ZDV and <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>. Results at 48 wks showed comparable outcomes (VL &lt;50in 37% of EFV pts and 32% of ATV pts). Low % achieving VL&lt;50 at 48 wks in both arms inconsistent with results from other EFV trials and felt to be due preservative used in specimens submitted for VL determination. <br>
<br>
</li>
<li>Haas DW, Zala C, Schrader S, et al.;
		Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial.;        
		AIDS;
		2003; Vol. 
		17; pp. 
		1339-49;
		<br>ISSN:
	        	0269-9370;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=12799555&amp;dopt=abstract" target="_new">12799555</a>
<br>
<b>Comments:</b>Compared ATV/<A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> (400/1200 mg qd), ATV/<A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> (600/1200 mg qd) and <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A>/<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> (400/400 mg bid), each with 2 NRTIs in pts with virologic failure on PI-based HAART regimens. At 48 wks, comparable efficacy across groups with mean VLL decreases of 1.44, 1.19 and 1.66 logs (p = NS). VL &lt;400 achieved in 41, 29 and 35% (p = NS), respectively. Pts receiving ATV had significantly better post-therapy lipid profiles and fewer GI side effects. Obvious limitation of this trial is the comparison to a PI combination (<A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> 400/<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 400 mg bid) that is no longer routinely used. <br>
<br>
</li>
</ol>
<br>
</td>
</tr>
</table>
</td><td></td>
</tr>
</table>
<p></p>
<table cellpadding="0" cellspacing="0" border="0" >
<tr>
<td bgcolor="#003366"></td><td class="bottomNav" bgcolor="#003366" >
<center>
<span class="copyrightFullModule">Copyright 2000-2008 Johns Hopkins University.  All rights reserved.</span>
</center>
</td>
</tr>
</table>
</body>

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_atazanavir.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:24:49 GMT -->
</html>
